SpinaFX Medical’s Triojection earned the FDA’s breakthrough device designation, according to an Aug. 15 news release.
Triojection is a minimally invasive, image-guided procedure to reduce pressure within the disc and alleviate nerve compression for lumbar disc herniation patients.
With breakthrough designation, the flagship device will have prioritized access to the FDA for regulatory processes.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.